The Center for Neuroscience and Behavior at American University (AU) in Washington, DC, with support from the Association for Public Policy Analysis and Management (APPAM), the Health Law and Policy Program at the Washington College of Law, AU’s Department of Neuroscience, and the Food & Drug Law Institute are sponsoring a symposium titled “The Therapeutic Use of Psychedelic Drugs: Legal, Policy and Neuroscientific Perspectives” on April 12, 2024, at the Washington College of Law (WCL) in Washington DC.
The symposium will bring together internationally recognized experts to speak on the following topics: (1) The science underlying what is known about the effects of psychedelic drugs on the brain; (2) The clinical science evaluating the efficacy of these drugs in the treatment of psychiatric and behavioral disorders; (3) Ethical ramifications of research and therapies involving psychedelic drugs; (4) Legal and policy perspectives on the regulation of psychedelic drug research and therapies; (5) Patents and commercialization; (6) Patient perspectives on the efficacy of drug therapies; and (7) Use of psychedelic substances by indigenous and underserved populations.
The organizers of the symposium are Professors Susan Carle, Lewis Grossman, and Asha Scielzo of the Washington College of Law, Professor Erdal Tekin of the School of Public Affairs, and Professors Anthony Riley and Terry Davidson of the Department of Neuroscience and the Center for Neuroscience and Behavior at AU.
Learn more here.